Baker Bros. Advisors Lp Buys ACADIA Pharmaceuticals Inc, Amarin Corp PLC, Clementia Pharmaceuticals Inc, Sells Sage Therapeutics Inc, Invitae Corp, Endocyte Inc

• New Purchases: GX1N, SRRA,
• Added Positions: ACAD, AMRN, CMTA, KRYS, BOLD, RARX, ZYME, GWPH, AGLE,
• Reduced Positions: GHDX, NVTA, NBIX, GLPG, ARRY, XNCR, SGMO, HALO, MYOK, BLUE, AUTL, NTLA, ABEO, FOMX, GLMD, CCXI, ACHN, ALKS, YMAB,
• Sold Out: SAGE, ECYT, ERYP, MNTA, ARWR, OVID,

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

1. Seattle Genetics Inc (SGEN) - 51,046,060 shares, 23.97% of the total portfolio.
2. Incyte Corp (INCY) - 34,251,607 shares, 18.05% of the total portfolio.
3. BeiGene Ltd (BGNE) - 11,959,824 shares, 13.90% of the total portfolio.
4. Alexion Pharmaceuticals Inc (ALXN) - 8,555,894 shares, 6.90% of the total portfolio.
5. Genomic Health Inc (GHDX) - 11,744,010 shares, 6.27% of the total portfolio. Shares reduced by 14.84%

Baker Bros. Advisors Lp initiated holding in Marker Therapeutics Inc. The purchase prices were between $3.68 and $7.94, with an estimated average price of $6.29. The stock is now traded at around $5.23. The impact to a portfolio due to this purchase was 0.07%. The holding were 1,500,000 shares as of .

Baker Bros. Advisors Lp initiated holding in Sierra Oncology Inc. The purchase prices were between $1.1 and $1.94, with an estimated average price of $1.59. The stock is now traded at around $1.83. The impact to a portfolio due to this purchase was 0.02%. The holding were 2,000,000 shares as of .

Baker Bros. Advisors Lp added to a holding in ACADIA Pharmaceuticals Inc by 39.65%. The purchase prices were between $14.32 and $22.92, with an estimated average price of $19.3. The stock is now traded at around $26.19. The impact to a portfolio due to this purchase was 1.51%. The holding were 39,713,842 shares as of .

Baker Bros. Advisors Lp added to a holding in Amarin Corp PLC by 25.02%. The purchase prices were between $12.41 and $22.98, with an estimated average price of $18.17. The stock is now traded at around $17.51. The impact to a portfolio due to this purchase was 0.96%. The holding were 42,592,824 shares as of .

Baker Bros. Advisors Lp added to a holding in Clementia Pharmaceuticals Inc by 92.61%. The purchase prices were between $9.21 and $15.69, with an estimated average price of $12.52. The stock is now traded at around $25.86. The impact to a portfolio due to this purchase was 0.17%. The holding were 3,724,445 shares as of .

Baker Bros. Advisors Lp added to a holding in Krystal Biotech Inc by 584.26%. The purchase prices were between $15.03 and $25.38, with an estimated average price of $21.04. The stock is now traded at around $27.34. The impact to a portfolio due to this purchase was 0.12%. The holding were 784,674 shares as of .

Baker Bros. Advisors Lp added to a holding in Ra Pharmaceuticals Inc by 362.55%. The purchase prices were between $11.58 and $18.31, with an estimated average price of $15.65. The stock is now traded at around $24.20. The impact to a portfolio due to this purchase was 0.09%. The holding were 823,113 shares as of .

Baker Bros. Advisors Lp added to a holding in Audentes Therapeutics Inc by 131.54%. The purchase prices were between $18.43 and $36.7, with an estimated average price of $25.59. The stock is now traded at around $36.22. The impact to a portfolio due to this purchase was 0.09%. The holding were 910,463 shares as of .

Baker Bros. Advisors Lp sold out a holding in Sage Therapeutics Inc. The sale prices were between $81.94 and $139.71, with an estimated average price of $113.76.

Baker Bros. Advisors Lp sold out a holding in Endocyte Inc. The sale prices were between $14.93 and $24, with an estimated average price of $22.16.

Baker Bros. Advisors Lp sold out a holding in Erytech Pharma SA. The sale prices were between $5.54 and $9.23, with an estimated average price of $7.45.

Baker Bros. Advisors Lp sold out a holding in Momenta Pharmaceuticals Inc. The sale prices were between $10.32 and $22.99, with an estimated average price of $13.68.

Baker Bros. Advisors Lp sold out a holding in Arrowhead Pharmaceuticals Inc. The sale prices were between $10.74 and $19.7, with an estimated average price of $13.53.

Baker Bros. Advisors Lp sold out a holding in Ovid Therapeutics Inc. The sale prices were between $2.42 and $6.6, with an estimated average price of $4.52.